These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 37993894)

  • 1. Understanding factors associated with the trajectory of subjective cognitive complaints in groups with similar objective cognitive trajectories.
    Cacciamani F; Bercu A; Bouteloup V; Grasset L; Planche V; Chêne G; Dufouil C;
    Alzheimers Res Ther; 2023 Nov; 15(1):205. PubMed ID: 37993894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subjective Cognitive Complaints: Comparing the Relation between Self-Reported Versus Informant-Reported Subjective Cognitive Complaints and Cognitive Performances in Cognitively Unimpaired, Mild Cognitive Impairment and Populations with Dementia.
    Peng SW; Wang CY; Lin SY; Lee YL; Lin YC; Lin YJ; Wang PN
    J Prev Alzheimers Dis; 2023; 10(3):562-570. PubMed ID: 37357298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The SNP rs6859 in NECTIN2 gene is associated with underlying heterogeneous trajectories of cognitive changes in older adults.
    Rajendrakumar AL; Arbeev KG; Bagley O; Yashin AI; Ukraintseva S;
    BMC Neurol; 2024 Feb; 24(1):78. PubMed ID: 38408961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuropsychiatric and Cognitive Symptoms Across the Alzheimer Disease Clinical Spectrum: Cross-sectional and Longitudinal Associations.
    Eikelboom WS; van den Berg E; Singleton EH; Baart SJ; Coesmans M; Leeuwis AE; Teunissen CE; van Berckel BNM; Pijnenburg YAL; Scheltens P; van der Flier WM; Ossenkoppele R; Papma JM
    Neurology; 2021 Sep; 97(13):e1276-e1287. PubMed ID: 34413181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trajectories of subjective cognitive decline, and the risk of mild cognitive impairment and dementia.
    Liew TM
    Alzheimers Res Ther; 2020 Oct; 12(1):135. PubMed ID: 33109275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum.
    Jansen WJ; Janssen O; Tijms BM; Vos SJB; Ossenkoppele R; Visser PJ; ; Aarsland D; Alcolea D; Altomare D; von Arnim C; Baiardi S; Baldeiras I; Barthel H; Bateman RJ; Van Berckel B; Binette AP; Blennow K; Boada M; Boecker H; Bottlaender M; den Braber A; Brooks DJ; Van Buchem MA; Camus V; Carill JM; Cerman J; Chen K; Chételat G; Chipi E; Cohen AD; Daniels A; Delarue M; Didic M; Drzezga A; Dubois B; Eckerström M; Ekblad LL; Engelborghs S; Epelbaum S; Fagan AM; Fan Y; Fladby T; Fleisher AS; Van der Flier WM; Förster S; Fortea J; Frederiksen KS; Freund-Levi Y; Frings L; Frisoni GB; Fröhlich L; Gabryelewicz T; Gertz HJ; Gill KD; Gkatzima O; Gómez-Tortosa E; Grimmer T; Guedj E; Habeck CG; Hampel H; Handels R; Hansson O; Hausner L; Hellwig S; Heneka MT; Herukka SK; Hildebrandt H; Hodges J; Hort J; Huang CC; Iriondo AJ; Itoh Y; Ivanoiu A; Jagust WJ; Jessen F; Johannsen P; Johnson KA; Kandimalla R; Kapaki EN; Kern S; Kilander L; Klimkowicz-Mrowiec A; Klunk WE; Koglin N; Kornhuber J; Kramberger MG; Kuo HC; Van Laere K; Landau SM; Landeau B; Lee DY; de Leon M; Leyton CE; Lin KJ; Lleó A; Löwenmark M; Madsen K; Maier W; Marcusson J; Marquié M; Martinez-Lage P; Maserejian N; Mattsson N; de Mendonça A; Meyer PT; Miller BL; Minatani S; Mintun MA; Mok VCT; Molinuevo JL; Morbelli SD; Morris JC; Mroczko B; Na DL; Newberg A; Nobili F; Nordberg A; Olde Rikkert MGM; de Oliveira CR; Olivieri P; Orellana A; Paraskevas G; Parchi P; Pardini M; Parnetti L; Peters O; Poirier J; Popp J; Prabhakar S; Rabinovici GD; Ramakers IH; Rami L; Reiman EM; Rinne JO; Rodrigue KM; Rodríguez-Rodriguez E; Roe CM; Rosa-Neto P; Rosen HJ; Rot U; Rowe CC; Rüther E; Ruiz A; Sabri O; Sakhardande J; Sánchez-Juan P; Sando SB; Santana I; Sarazin M; Scheltens P; Schröder J; Selnes P; Seo SW; Silva D; Skoog I; Snyder PJ; Soininen H; Sollberger M; Sperling RA; Spiru L; Stern Y; Stomrud E; Takeda A; Teichmann M; Teunissen CE; Thompson LI; Tomassen J; Tsolaki M; Vandenberghe R; Verbeek MM; Verhey FRJ; Villemagne V; Villeneuve S; Vogelgsang J; Waldemar G; Wallin A; Wallin ÅK; Wiltfang J; Wolk DA; Yen TC; Zboch M; Zetterberg H
    JAMA Neurol; 2022 Mar; 79(3):228-243. PubMed ID: 35099509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utility of an Alzheimer's Disease Risk-Weighted Polygenic Risk Score for Predicting Rates of Cognitive Decline in Preclinical Alzheimer's Disease: A Prospective Longitudinal Study.
    Porter T; Burnham SC; Milicic L; Savage G; Maruff P; Lim YY; Li QX; Ames D; Masters CL; Rainey-Smith S; Rowe CC; Salvado O; Groth D; Verdile G; Villemagne VL; Laws SM;
    J Alzheimers Dis; 2018; 66(3):1193-1211. PubMed ID: 30412495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perceived social isolation is correlated with brain structure and cognitive trajectory in Alzheimer's disease.
    Zhang Y; Tatewaki Y; Liu Y; Tomita N; Nagasaka T; Muranaka M; Yamamoto S; Takano Y; Nakase T; Mutoh T; Taki Y
    Geroscience; 2022 Jun; 44(3):1563-1574. PubMed ID: 35526259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimizing detection of Alzheimer's disease in mild cognitive impairment: a 4-year biomarker study of mild behavioral impairment in ADNI and MEMENTO.
    Ismail Z; Leon R; Creese B; Ballard C; Robert P; Smith EE
    Mol Neurodegener; 2023 Jul; 18(1):50. PubMed ID: 37516848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are subjective memory complaints indicative of objective cognitive decline or depressive symptoms? Findings from the English Longitudinal Study of Ageing.
    Brailean A; Steptoe A; Batty GD; Zaninotto P; Llewellyn DJ
    J Psychiatr Res; 2019 Mar; 110():143-151. PubMed ID: 30639919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cerebrospinal fluid Aβ42 is the best predictor of clinical progression in patients with subjective complaints.
    van Harten AC; Visser PJ; Pijnenburg YA; Teunissen CE; Blankenstein MA; Scheltens P; van der Flier WM
    Alzheimers Dement; 2013 Sep; 9(5):481-7. PubMed ID: 23232269
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subjective Spatial Navigation Complaints - A Frequent Symptom Reported by Patients with Subjective Cognitive Decline, Mild Cognitive Impairment and Alzheimer's Disease.
    Cerman J; Andel R; Laczo J; Vyhnalek M; Nedelska Z; Mokrisova I; Sheardova K; Hort J
    Curr Alzheimer Res; 2018; 15(3):219-228. PubMed ID: 29165083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Internal Consistency Over Time of Subjective Cognitive Decline: Drawing Preclinical Alzheimer's Disease Trajectories.
    Ávila-Villanueva M; Maestú F; Fernández-Blázquez MA
    J Alzheimers Dis; 2018; 66(1):173-183. PubMed ID: 30248053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validity and Performance of Blood Biomarkers for Alzheimer Disease to Predict Dementia Risk in a Large Clinic-Based Cohort.
    Planche V; Bouteloup V; Pellegrin I; Mangin JF; Dubois B; Ousset PJ; Pasquier F; Blanc F; Paquet C; Hanon O; Bennys K; Ceccaldi M; Annweiler C; Krolak-Salmon P; Godefroy O; Wallon D; Sauvee M; Boutoleau-Bretonnière C; Bourdel-Marchasson I; Jalenques I; Chene G; Dufouil C;
    Neurology; 2023 Jan; 100(5):e473-e484. PubMed ID: 36261295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Race, APOEɛ4, and Long-Term Cognitive Trajectories in a Biracial Population Sample.
    Rajan KB; McAninch EA; Wilson RS; Weuve J; Barnes LL; Evans DA
    J Alzheimers Dis; 2019; 72(1):45-53. PubMed ID: 31561363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alzheimer's disease genetic risk and cognitive reserve in relationship to long-term cognitive trajectories among cognitively normal individuals.
    Pettigrew C; Nazarovs J; Soldan A; Singh V; Wang J; Hohman T; Dumitrescu L; Libby J; Kunkle B; Gross AL; Johnson S; Lu Q; Engelman C; Masters CL; Maruff P; Laws SM; Morris JC; Hassenstab J; Cruchaga C; Resnick SM; Kitner-Triolo MH; An Y; Albert M
    Alzheimers Res Ther; 2023 Mar; 15(1):66. PubMed ID: 36978190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study.
    Dubois B; Epelbaum S; Nyasse F; Bakardjian H; Gagliardi G; Uspenskaya O; Houot M; Lista S; Cacciamani F; Potier MC; Bertrand A; Lamari F; Benali H; Mangin JF; Colliot O; Genthon R; Habert MO; Hampel H;
    Lancet Neurol; 2018 Apr; 17(4):335-346. PubMed ID: 29500152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ADAM10 plasma levels predict worsening in cognition of older adults: a 3-year follow-up study.
    Oliveira Monteiro MPA; Salheb Oliveira DSM; Manzine PR; Crispim Nascimento CM; Dos Santos Orlandi AA; de Oliveira Gomes GA; Dos Santos Orlandi F; Zazzetta MS; Pott-Junior H; Cominetti MR
    Alzheimers Res Ther; 2021 Jan; 13(1):18. PubMed ID: 33419480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of
    Qian J; Betensky RA; Hyman BT; Serrano-Pozo A
    Neurology; 2021 May; 96(19):e2414-e2428. PubMed ID: 33771840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impacts of baseline biomarkers on cognitive trajectories in subjective cognitive decline: the CoSCo prospective cohort study.
    Hong YJ; Ho S; Jeong JH; Park KH; Kim S; Wang MJ; Choi SH; Yang DW;
    Alzheimers Res Ther; 2023 Aug; 15(1):132. PubMed ID: 37550761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.